Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Associate Professor of Cell Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information

  • Email Address:
  • Websites:


  • B.S. University of Kentucky, 2002
  • Ph.D. Massachusetts Institute of Technology, 2007

Courses Taught

  • CMB 710B: Cell & Molecular Biology Module II
  • CMB 710E: Cell & Molecular Biology Module V
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

In the News

Representative Publications

  • Goodwin, Craig M., Andrew M. Waters, Jennifer E. Klomp, Sehrish Javaid, Kirsten L. Bryant, Clint A. Stalnecker, Kristina Drizyte-Miller, et al. “Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.” Cancer Res, November 8, 2022.
  • Wood, Kris C., and J Silvio Gutkind. “Challenges and Emerging Opportunities for Targeting mTOR in Cancer.” Cancer Res 82, no. 21 (November 2, 2022): 3884–87.
  • Lidsky, Michael E., Zechen Wang, Min Lu, Annie Liu, S David Hsu, Shannon J. McCall, Zhecheng Sheng, et al. “Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.” Npj Precis Oncol 6, no. 1 (October 23, 2022): 75.
  • Kishton, Rigel J., Shashank J. Patel, Amy E. Decker, Suman K. Vodnala, Maggie Cam, Tori N. Yamamoto, Yogin Patel, et al. “Cancer genes disfavoring T cell immunity identified via integrated systems approach.” Cell Rep 40, no. 5 (August 2, 2022): 111153.
  • Lin, Kevin H., Justine C. Rutter, Abigail Xie, Shane T. Killarney, Camille Vaganay, Chaima Benaksas, Frank Ling, et al. “P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.” Nat Cancer 3, no. 7 (July 2022): 837–51.